RSS | Login | Register

BARACLUDE

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare BARACLUDE to:

Generic Name for BARACLUDE

Entecavir 0.5mg, 1mg; tabs.

Legal Classification:

Pharmacological Class for BARACLUDE

Nucleoside analogue (HBV polymerase inhibitor).

Manufacturer of BARACLUDE

Bristol-Myers Squibb

Indications for BARACLUDE

Chronic hepatitis B infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Adult dose for BARACLUDE

≥16yrs: Take on empty stomach. Nucleoside-naive: 0.5mg once daily. Lamivudine-refractory: 1mg once daily. Renal impairment (nucleoside-naive): CrCl 30–49mL/min: 0.25mg once daily or 0.5mg every 48 hours; CrCl 10–29mL/min: 0.15mg once daily or 0.5mg every 72 hours; CrCl <10mL/min: 0.05mg once daily or 0.5mg every 7 days; lamivudine-refractory: see literature. Give after hemodialysis.

Children's dosing for BARACLUDE

<16yrs: not recommended.

Also:

BARACLUDE ORAL SOLUTION

Warnings/Precautions for BARACLUDE

Renal impairment (see Dose). HIV/HBV co-infected patients not receiving highly active antiretroviral therapy (HAART): not recommended. HIV antibody testing recommended before starting therapy. Monitor hepatic function during and for several months after ending therapy (risk of hepatitis B reactivation). Liver transplant. Reevaulate periodically. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for BARACLUDE

May potentiate or be potentiated by drugs that reduce renal function or compete for active tubular secretion. May increase resistance to HIV drugs in HIV patients not on HAART.

Adverse Reactions for BARACLUDE

Headache, fatigue, GI upset; rare: lactic acidosis, severe hepatomegaly with steatosis (may be fatal), post-treatment severe, acute exacerbation of hepatitis.

Notes for BARACLUDE

How is BARACLUDE supplied?

Tabs 0.5mg—30, 90
1mg—30
Soln—210mL (w. dosing spoon)

Related Disease:

Hepatitis~antivirals

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).